Champions Oncology Ownership
| CSBR Stock | USD 4.18 0.37 8.13% |
Shares in Circulation | First Issued 1995-12-31 | Previous Quarter 13.6 M | Current Value 14 M | Avarage Shares Outstanding 5.3 M | Quarterly Volatility 5.1 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Champions |
Champions Stock Ownership Analysis
About 26.0% of the company shares are held by company insiders. The company has Price/Earnings (P/E) ratio of 220.0. Champions Oncology recorded a loss per share of 0.24. The entity had not issued any dividends in recent years. The firm had 1:12 split on the 12th of August 2015. Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey. Champions Oncolog operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 230 people. For more info on Champions Oncology please contact Ronnie MD at 201 808 8400 or go to https://www.championsoncology.com.Besides selling stocks to institutional investors, Champions Oncology also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Champions Oncology's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Champions Oncology's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Champions Oncology Quarterly Liabilities And Stockholders Equity |
|
Champions Oncology Insider Trades History
About 26.0% of Champions Oncology are currently held by insiders. Unlike Champions Oncology's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Champions Oncology's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Champions Oncology's insider trades
Champions Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Champions Oncology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Champions Oncology backward and forwards among themselves. Champions Oncology's institutional investor refers to the entity that pools money to purchase Champions Oncology's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bank Of New York Mellon Corp | 2024-06-30 | 26.7 K | State Street Corp | 2024-06-30 | 26.6 K | Bank Of America Corp | 2024-06-30 | 25.3 K | Cambridge Invest Research Advisors, Inc. | 2024-09-30 | 12.3 K | Mesirow Fin Investmt Mgmt Intl Equity | 2024-09-30 | 12 K | Stifel Financial Corp | 2024-06-30 | 10.9 K | Simplex Trading, Llc | 2024-06-30 | 3 K | Ubs Group Ag | 2024-06-30 | 379 | Royal Bank Of Canada | 2024-06-30 | 133 | Battery Management Corp | 2024-09-30 | 2.4 M | Nea Management Company, Llc | 2024-06-30 | 1.7 M |
Champions Oncology Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Champions Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Champions Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Champions Oncology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Champions Oncology Outstanding Bonds
Champions Oncology issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Champions Oncology uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Champions bonds can be classified according to their maturity, which is the date when Champions Oncology has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Champions Oncology Corporate Filings
F4 | 18th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
| 30th of October 2024 Other Reports | ViewVerify | |
8K | 15th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Pair Trading with Champions Oncology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Champions Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Champions Oncology will appreciate offsetting losses from the drop in the long position's value.Moving against Champions Stock
The ability to find closely correlated positions to Champions Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Champions Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Champions Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Champions Oncology to buy it.
The correlation of Champions Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Champions Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Champions Oncology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Champions Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Champions Stock Analysis
When running Champions Oncology's price analysis, check to measure Champions Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Champions Oncology is operating at the current time. Most of Champions Oncology's value examination focuses on studying past and present price action to predict the probability of Champions Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Champions Oncology's price. Additionally, you may evaluate how the addition of Champions Oncology to your portfolios can decrease your overall portfolio volatility.